Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to demonstrate benefit with respect to hematopoietic response in
subjects with anemia of cancer randomized to Darbepoetin Alfa once every 4 weeks.